科素亚对原发性高血压患者降压疗效及安全性观察
高血压,,科素亚；高血压,1资料与方法,2结果,3讨论,【参考文献】
【摘要】 目的 观察血管紧张素Ⅱ受体拮抗剂科素亚(Cozaar,化学成分：氯沙坦)对轻、中度原发性高血压患者的降压疗效及安全性。方法 门诊选取轻、中度原发性高血压患者76例，服用科素亚50mg，或加服双氢克尿塞片12.5~25mg，1次/d，测定服药前及服药后2、4、6、8周时的坐位血压和心率，并测定服药前和服药8周后的立位血压、尿蛋白、尿糖、血肌酐、血电解质。结果 单用科素亚或加用双氢克尿塞后8周，坐位血压下降总有效率为78.68%，其中显效48.52%，血压由服药前(156.83±10.36/97.56±4.13)mmHg下降为(132.76±8.75/82.38±5.78)mmHg，血压下降差异有显著性(P<0.001)，立位血压由服药前(154.84±10.86/93.47±4.87)mmHg下降为(133.75±9.80/81.96±5.78)mmHg，血压下降差异有显著性(P<0.001)，但未见直立性低血压发生；用药前后心率、尿糖、血肌酐及血电解质无明显改变，尿蛋白有减少。结论 科素亚作为血管紧张素Ⅱ受体拮抗剂，用于治疗轻、中度原发性高血压者，既安全又有效。【关键词】 科素亚；高血压
The clinical efficacy and safety of Cozaar in treatment of patients with essential hypertension
LI Rui.
The East China Petrob Leum Hospital,Yangzhou 225003，China
【Abstract】 Objective To investigate the efficacy and safety of Cozaar in treatment of essential hypertension patients.Methods Seventy six patients with essential hypertension received Cozaar 50 mg daily for 8 weeks.For some nonresponded patients hydrochlorothiazide(12.5mg/25mg daily)was added.Results Cozaar reduced sitting blood pressure from(156.83±10.36/97.56±4.13)mmHg to(132.76±8.75/82.38±5.78)mmHg(P<0.001).Meanwhile standing blood pressure was reduced from(154.84±10.86/93.47±4.87)mmHg to(133.75±9.80/81.76±5.78)mmHg(P<0.001),and no patients had orthostatic hypotension caused by Cozaar.The effective rate of Cozaar is 78.68%.Cozaar also reduced proteinuria.Conclusion In mildmoderate essential hypertensive patients,Cozaar is effective and well tolerated and offers a promising approach to the treatment of hypertension. ......
您现在查看是摘要页，全文长 7169 字符。